No Data
Verrica Pharmaceuticals Is Maintained at Outperform by RBC Capital
RBC Lowers Price Target on Verrica Pharmaceuticals to $11 From $13, Keeps Outperform, Speculative Risk
12 Health Care Stocks Moving In Thursday's Intraday Session
This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Verrica Pharmaceuticals Price Target Maintained With a $12.00/Share by Needham
Verrica Pharmaceuticals Shares Are Trading Lower After the Company Announced a Structuring to Reduce Costs and Expand Access to YCANTH for the Treatment of Molluscum Contagiosum. Also, Brookline Capital Downgraded the Stock From Buy to Hold.